

*This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.*

*This English version is intended to be a reference material to provide convenience for users.*

*In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

# Revision of PRECAUTIONS

## Imeglimin hydrochloride

January 13, 2026

### **Therapeutic category**

Antidiabetic agents

### **Non-proprietary name**

Imeglimin hydrochloride

### **Safety measure**

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

Current	Revision
11. ADVERSE REACTIONS	11. ADVERSE REACTIONS
11.1 Clinically Significant Adverse Reactions (newly)	11.1 Clinically Significant Adverse Reactions <u>Severe decreased appetite, vomiting</u> <u>Cases with decreased appetite and vomiting, leading to dehydration</u> <u>have been reported.</u>